You just read:

AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis

News provided by

AbbVie

Aug 16, 2019, 12:43 ET